Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Stock Report

| More

Sanofi India Ltd announces slump sale and transfer of Ankleshwar manufacturing facility

Posted On: 2019-09-11 11:56:35

The Board of Directors of Sanofi India Limited (the Company) at its meeting held on 10th September 2019 approved a transaction for the slump sale and transfer of the manufacturing facility of the Company at Ankleshwar, Gujarat to Zentiva Private Limited for a consideration of Rs. 2,617 million, subject to customary working capital adjustments. This transaction is subject to approval of the members, which will be initiated by the Company through a postal ballot process and few other conditions as defined under the Business Transfer Agreement.

In 2018, as part of a global transaction between Sanofi Group and Advent International, Advent acquired Zentiva, Sanofi Group's European generics business. Following this transaction, Zentiva continued to source products from the Company (through Sanofi group) for its generics business pursuant to a five-year supply agreement (ending in 2023). In view of this transaction, the commercial part of this business was divested by Sanofi group to Advent, while the manufacturing assets continued to be in the Company.

Having received an offer from Zentiva to acquire its manufacturing facility in Ankleshwar, the Company agreed to explore this opportunity as it was in line with its' broader strategic direction. In particular, (i) it was an opportunity to address the excess and unutilized manufacturing capacity that would have remained at the end of the supply agreement, (ii) it supported the focus on manufacturing Sanofi branded products rather than manufacturing for third parties, and (iii) it would improve asset efficiency ratios.

The Board has also taken into consideration the valuation report issued by Deloitte Touche Tohmatsu India LLP and a fairness opinion on such valuation issued by ICICI Securities Limited.

Given the above and considering that the two companies share similar values and commitment towards serving patients and their employees, the Board of Directors of Sanofi India Limited approved this transaction in the long-term interest of all stakeholders.

After closing of the transaction and receipt of the consideration, the Board will consider the best utilization of the proceeds for business development including distribution to the shareholders in an appropriate manner.

The Ankleshwar manufacturing facility is engaged in the manufacture of Active Pharmaceutical Ingredients (API) and finished pharmaceutical products for distribution / sales across the world. In the financial year ended 31st December 2018, this facility contributed Rs. 8,735 million in the revenue (34% of total revenue of the Company including Rs. 6,226 million of domestic sales that will not be impacted), and Rs. 2,945 million to the net worth (13% of total net worth of the Company). Apart from manufacturing products which are exported to Zentiva, it also makes products which are not part of the divestment. The products for domestic market which are being manufactured at the Ankleshwar manufacturing facility will be moved to another manufacturing facility of the Company and will continue to be in the product portfolio of the Company, while most Zentiva export products that were manufactured at the Goa facility will be transferred to the Ankleshwar site. The Company has made necessary arrangements to handle this transition in a secure manner to ensure that there is no business disruption in the supplies of products which have not been divested. Post this transition, the estimated average annual revenue loss to the Company over a period of the next 4 years (balance of five-year supply agreement mentioned above) is about Rs.4,700 million. The Company plans to mitigate the loss of profit in due course through renewed focus on its core activities and brands.

Shares of Sanofi India Ltd was last trading in BSE at Rs.6271.3 as compared to the previous close of Rs. 6178.75. The total number of shares traded during the day was 209 in over 158 trades.

The stock hit an intraday high of Rs. 6297.85 and intraday low of 6150. The net turnover during the day was Rs. 1301421.

Source: Equity Bulls

Click here to send ur comments or to

Other Headlines:

Ambuja Cements Ltd Q4 CY2019 consolidated PAT lower at Rs. 591.54 crore

ICRA revises long term rating of Indiabulls Housing Finance Limited

GMR Infrastructure Limited announces Strategic Partnership with Groupe ADP for Airports Business

Muthoot Finance Ltd announces pricing of USD 550 million 4.40% notes

UFO Moviez India Ltd board to consider interim dividend on Feb 27, 2020

Dr. Reddy's Laboratories Ltd receives EIR for Duvvada Formulations Plant

Dhanlaxmi Bank Ltd receives RBI nod for appointment of MD & CEO

Sharda Cropchem Ltd Board to consider Second Interim Dividend for FY20

Ambuja Cements Ltd Board recommends Dividend of Rs. 1.50 for CY2019

Plastiblends India Ltd board to consider interim dividend on Feb 25, 2020

Cyient Organizes Blood Donation Drive at its Hyderabad Campus

TCS Named as One of the Fortune Best Big Companies to Work For™ in 2020

India Infoline Finance Ltd raises $400 million

Ambuja Cements Limited appoints Mr. Neeraj Akhoury as new MD and CEO

Garware Technical Fibres Ltd to dispose business undertaking in USA

AstraZeneca Pharma India Ltd launches FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets (QTERN®)

DCW Limited is the biggest beneficiary of the recently announced anti-dumping duty on imported C-PVC

Jubilant FoodWorks Ltd Board to consider interim dividend on Feb 27, 2020

Jubilant Life Sciences Ltd board to consider interim dividend for FY2020

JK Paper Ltd board to consider interim dividend on Feb 27, 2020

Shri N Baijendra Kumar, CMD, NMDC wins Business Leadership Award

Cyril Amarchand Mangaldas Advises Avenue Supermarts Limited on its INR 4098 Cr. QIP

PVR Ltd board to declare interim dividend on Feb 28, 2020

ICRA assigns ratings to KPIT Technologies Ltd

A.M. Best Affirms A-(Excellent) Rating of The New India Assurance Company Limited

Cipla Ltd board to consider interim dividend for FY2020

SBI Cards IPO to open for subscription on March 2, 2020

Axis Bank to explore long-term strategic partnership with Max Life

Genus Power wins 'Innovative Initiative in the Power Sector', 2020 award for its Smart Metering Pilot project in UAE

JK Cement Ltd board to consider interim dividend on Feb 28, 2020

Shoppers Stop Ltd closes stores at Orion East Mall, Bengaluru and Grant Mall, Chennai

KRBL Ltd board to consider interim dividend for FY2020

Future Lifestyle Fashions Ltd board approves issue of securities to IFC

Trident Ltd board declares interim dividend of Rs. 0.18

Century Plyboards India Ltd forms new subsidiary company

Valiant Organics Ltd board to consider 2nd interim dividend on Feb 28, 2020

Sonata Software Ltd board to consider interim dividend on Feb 26, 2020

JB Chemicals & Pharmaceuticals Ltd board declares interim dividend of Rs. 10

Anuh Pharma Ltd receives CEP for Ambroxol Hydrochloride for EU market

TCS Positioned as a Leader in Application Transformation Services by Everest Group

CARE Ratings Limited updates on ratings of Pitti Engineering Ltd

HGS Recognized on IAOP's 'The 2020 Global Outsourcing 100®' List

Shreyas Shipping & Logistics Ltd announces sale of Vessel 'SSL Kutch'

Redington India Ltd board approves 2nd interim dividend of Rs. 2.80

Cholamandalam Investment and Finance Company Ltd board to consider interim dividend for FY20

Tarini International Ltd updates on SEBI AO Order

Sunteck Realty Ltd has sold 1800 apartments at Sunteck MaxXWorld

Thomas Cook India Ltd board to consider buy back on Feb 26, 2020

Delhi International Airport Ltd offers $150 mn senior secured notes

IndiGo to enable faster ground operations and reduce aircraft turn-around time with WheelTug Systems

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019